Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)
December 13 2022 - 7:00AM
Business Wire
- New preclinical results presented at SABCS demonstrate LP-184
has superior anti-tumor efficacy for TNBC, as compared to current
TNBC standard of care agents.
- LP-184 has therapeutic potential not only for primary TNBCs,
but also for brain metastases (mets.) stemming from primary TNBC
tumors.
- Each year in the US, there are approximately 8,000 newly
diagnosed TNBC patients with an additional 21,000 relapsed TNBC
patients, representing an annual market potential of up to $1.7
billion USD.
- Expanding LP-184's development indications to include TNBC
further increases the long-term, potential value of LP-184 across
multiple solid tumors that have unmet or underserved patient
needs.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("A.I.") and machine learning (“M.L.”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced that it has expanded development
of its drug candidate LP-184 to include Triple Negative Breast
Cancer (TNBC), one of the most aggressive and malignant forms of
breast cancer. New positive preclinical data on the anti-tumor
potency of LP-184 for TNBCs was recently presented at the San
Antonio Breast Cancer Symposium (SABCS) 2022.
“As many as 20% of all breast cancers are TNBCs, which are
tumors that do not express receptors for Estrogen, Progesterone, or
HER2. Therefore, drugs targeted at these receptors are not a
therapeutic option for TNBC patients. The prognosis of TNBC
patients is considerably worse than HR positive breast cancers,
with over 50% of patients relapsing in the first 3 to 5 years and
metastatic TNBC patients having a median overall survival of less
than a year. Due to the poor prognosis and high relapse rate of
TNBC, it is imperative to develop new and effective drug candidates
for these patients.” stated Kishor Bhatia, Ph.D., Lantern’s Chief
Scientific Officer.
The SABCS poster highlights new preclinical results
demonstrating LP-184’s potent in vitro and in vivo anti-tumor
efficacy across a broad range of breast cancer models, including
TNBC models that are resistant to Olaparib, a PARP inhibitor
(PARPi) and a current standard of care (SOC) agent for TNBC. LP-184
had low nanomolar potency (average IC50 of 297nM) when tested
across a panel of 4 TNBC breast cancer cell lines. Considering
LP-184’s in vitro anti-tumor activity for TNBCs, LP-184 was
additionally tested in 10 patient derived xenograft (PDX) mouse
models of TNBCs, 7 of which were resistant to Olaparib. In all 10
TNBC PDX models, LP-184 treatment led to complete and durable tumor
regression of 107-141%.
In addition to LP-184’s preclinical anti-tumor efficacy for
primary TNBC tumors, LP-184 may also have added therapeutic
potential to treat brain metastases (brain mets.) from TNBCs, which
are found in ~14% of TNBC patients at their initial diagnosis.
LP-184 was previously shown to have anti-tumor activity in brain
mets. cell lines derived from breast, lung and skin cancers, and
was additionally shown to have up to 6X more in vitro anti-tumor
activity in comparison to multiple brain mets. SOC agents.
“Patients with primary and secondary TNBCs are in urgent need of
new and effective therapies. The combined anti-tumor potency of
LP-184 in PARPi resistant TNBC PDXs and LP-184’s distinct PARP
independent mechanisms, strongly support the potential of LP-184 to
be added to the treatment armamentarium for TNBC patients”
continued Dr. Bhatia.
A full version of the poster presentation from the SABCS
conference 2022 can be found on Lantern’s website.
About LP-184:
LP-184 is a small molecule drug candidate with a synthetically
lethal mechanism of action (MoA) that preferentially damages DNA in
cancer cells that harbor mutations in DNA damage repair (DDR) genes
and that overexpress the enzyme PTGR1. Lantern is developing LP-184
for genetically defined solid tumors including TNBC, pancreatic,
and bladder, as well as several central nervous system (CNS) tumors
including glioblastoma, brain mets., and atypical teratoid rhabdoid
tumors (ATRT).
LP-184 has been granted Orphan Drug Designation by the FDA for
the treatment of pancreatic cancer, malignant gliomas, and ATRT and
was also granted a Rare Pediatric Disease Designation for ATRT.
These designations and continued positive preclinical data will
help to accelerate LP-184 towards a targeted IND submission in Q1
2023 and first in human Phase 1 clinical trials anticipated to
commence in Q2 2023.
About Lantern Pharma:
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage
oncology-focused biopharmaceutical company leveraging its
proprietary RADR® A.I. and machine learning platform to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted therapeutics. Lantern is
currently developing four drug candidates and an ADC program across
twelve disclosed tumor targets, including two phase 2 programs. By
targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug,
Lantern's approach represents the potential to deliver
best-in-class outcomes.
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 10,
2022. You may access our Annual Report on Form 10-K for the year
ended December 31, 2021 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221213005431/en/
Nicole Leber Investor Relations Associate ir@lanternpharma.com
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma Monthly Newsletter: Sign-up here
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024